A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell L
A phase 3 trial of Pemetrexed, Carboplatin, Cisplatin in non-small-cell lung cancer and small-cell lung cancer, run by mAbxience Research S.L., active and no longer recruiting.
Overview
A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell Lung Cancer (BENITO Study) is a phase 3 interventional study registered as NCT06687369 by mAbxience Research S.L., with 726 participants planned, started 2024-12-30 and due to reach its primary completion in 2026-08-31. Interventions recorded: MB12 (Proposed Pembrolizumab Biosimilar), EU-sourced Keytruda®, US-sourced Keytruda®, Pemetrexed, Carboplatin. Conditions listed: Non Squamous Non Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialFirmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation
Shares Pemetrexed, Cisplatin, Carboplatin, Small-cell lung cancer.
- TrialA Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-S
Shares Pemetrexed, Cisplatin, Carboplatin, Small-cell lung cancer.
- TrialStudy of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
Shares Pemetrexed, Carboplatin, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialStudy of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer
Shares Pemetrexed, Carboplatin, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
Shares Pemetrexed, Carboplatin, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialStudy of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy
Shares Pemetrexed, Cisplatin, Carboplatin, Small-cell lung cancer.
- TrialStudy of BEBT-109 in Subjects With Non-Small Cell Lung Cancer Carrying EGFR Exon 20 Insertion Mutations
Shares Pemetrexed, Cisplatin, Carboplatin, Small-cell lung cancer.
- TrialA Phase III Study of SKB264 for EGFR Mutant NSCLC Patients
Shares Pemetrexed, Cisplatin, Carboplatin, Small-cell lung cancer.